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ABSTRACT
Background: With the rising incidence of type 1 diabetes (T1D) among young children, it is
important to understand factors related to management and outcomes in this population. Parental
fear of hypoglycemia (FOH) has been examined in relation to children’s glycemic control, but
findings have been inconsistent. Adherence has been offered as a potential mechanism, but this
has not been examined empirically with this population. This study aimed to elucidate the
relations among parental FOH, adherence, and glycemic control in young children with T1D.
Methods: Parents of children diagnosed with T1D before age 6 (n = 143) completed self-report
measures of anxiety, FOH, and adherence. Hemoglobin A1c (HbA1c) was obtained via medical
records or dried blood spots. Polynomial regressions were conducted to assess the fit of quadratic
relations between parental FOH and HbA1c, and between adherence and HbA1c, controlling for
parental anxiety. Results: The model predicting HbA1c from parental FOH was not significant,
F(3,138) = 2.668, p > .05. The model for adherence was significant, F(3,138) = 2.916, p < .05;
however, the relation was in the opposite direction of that hypothesized. Exploratory analysis
was conducted to assess the fit of a quadratic relation between low parental FOH and HbA1c.
Polynomial regression revealed a model that was significant, F(3,66) = 2.961, p < .05, that was
in the direction of that hypothesized, with an R2 of .119. Conclusions: Although the
hypothesized relations between parental FOH, adherence, and glycemic control were not
supported, preliminary support for nonlinear relations among these variables was demonstrated.
Future research should continue to investigate the level of parental FOH that is associated with
optimal management and outcomes for young children with T1D, and determine possible
mechanisms of this relation.
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INTRODUCTION
Diabetes
Diabetes is a disease characterized by high blood glucose levels (U.S. National Library of
Medicine, n.d.-b). Typically, the pancreas produces the hormone, insulin, that helps glucose
enter cells and provide them with energy. In diabetes, there are issues with producing or using
insulin effectively, resulting in blood glucose levels that are too high. According to the most
recent National Diabetes Statistics Report (Centers for Disease Control and Prevention, 2020), an
estimated 34.2 million people in the United States have diabetes, which represents 10.5% of the
population.
While there are several different types of diabetes, the three most common are type 1
diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes (National Institute of Diabetes
and Digestive and Kidney Diseases, 2016). In T1D, the immune system attacks and destroys the
cells in the pancreas that make insulin, thus the body ceases to produce any insulin. T1D
typically manifests in children and young adults, although it can be diagnosed at any age. In
T2D, the body does not produce enough insulin, or use insulin effectively. T2D can manifest at
any age, but it is observed more often among middle age and older populations. Some women
develop diabetes during pregnancy, which is termed gestational diabetes. This type of diabetes
typically resolves after the baby is born, although women who have had gestational diabetes are
at increased risk of developing T2D in the future (National Institute of Diabetes and Digestive
and Kidney Diseases, 2016).
T2D is the most prevalent type of diabetes, but youths are disproportionately affected by
T1D. In a study of incidence trends of diabetes among minors in the United States, in 2011-2012,
1

the estimated annual incidence of diagnosed T1D was 17,900 among youths ages 0–19, and the
estimated annual incidence of diagnosed T2D was 5,300 among youths ages 10–19 (MayerDavis et al., 2017). Children younger than age 10 who were diagnosed with T2D were excluded
from their analyses because the occurrence in their sample was so low. Further, evidence
suggests that the incidence of T1D among youths is increasing. Mayer-Davis et al. (2017)
estimated that the adjusted annual relative increase in the incidence of T1D among youths in the
US (ages 0–19) is 1.8%. Specifically, they estimated that the number of new cases increased
from approximately 15,900 in the 2002-2003 period to 17,900 in the 2011-2012 period. This
trend appears to be especially robust among young children. A European study, covering a
population of approximately 28 million children, reported annual rates of increase in incidence as
a function of age: 6.3%, 3.1%, and 2.4% in children ages 0–4, ages 5–9, and ages 10–14,
respectively (EURODIAB ACE Study Group, 2000).
T1D is a chronic autoimmune disease (Eisenbarth, 1986). It is currently conceptualized as
developing along a continuum consisting of three distinct stages (Insel et al., 2015). In Stage 1,
individuals test positive for two or more diabetes-related autoantibodies, but their blood glucose
levels are normal, and they do not display any symptoms. In Stage 2, blood glucose levels are
elevated. This is due to the loss of beta cells, the cells that produce insulin in the regions of the
pancreas known as the islets of Langerhans. Individuals in Stage 2 continue to display no
symptom, but in Stage 3, typical clinical symptoms emerge. This is typically when T1D is
diagnosed. A condition known as diabetic ketoacidosis (DKA) is present in approximately 30%
of newly diagnosed T1D cases among youth (Dabelea et al., 2014). Deprived of insulin, the body
breaks down fat to use as fuel, a process which leads to excessive acids (called ketones) in the
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blood and urine. Clinical manifestations of DKA include dehydration, shortness of breath,
nausea/vomiting/abdominal pain, confusion, and loss of consciousness (Wolfsdorf et al., 2009).
DKA is a serious condition that can be fatal if left untreated (Wolfsdorf et al., 2009). The
majority of children who enter Stage 1 progress to Stage 3, but progression time varies from
several weeks to many years (Knip et al., 2010; Ziegler et al., 2013). In a large, multinational
study of children who presented with multiple diabetes-related autoantibodies, approximately
44%, 70%, and 84% demonstrated symptomatic disease at 5-year, 10-year, and 15-year followup, respectively (Ziegler et al., 2013). Disease progression was faster in children younger than
age 3.
Once T1D is diagnosed, intense monitoring of glucose levels and compensatory insulin
therapy is indicated (American Diabetes Association, 2013). Many factors affect blood glucose
levels, such as food intake, physical activity, medications, illness, stress, and pain; but
maintaining near normal blood glucose levels plays an essential role in preventing diabetesrelated problems (American Diabetes Association, 2018). Blood glucose levels can be monitored
by pricking an area of the skin (typically fingertips) to obtain a drop of blood and placing the
blood on a test strip of a blood glucose meter (Benjamin, 2002). Glucose levels can also be
monitored using a continuous glucose monitor (CGM). Most CGMs consist of a sensor inserted
subcutaneously, a monitor that displays information, and a transmitter that transmits data
between the sensor and the monitor (Dungan & Verma, 2000). Both of these methods provide a
rating of current glucose levels. The hemoglobin A1c (HbA1c) test is used to provide
information about average blood glucose levels over the previous two- to three-month period and
is used as a marker of glycemic control (Agiostratidou et al., 2017; American Diabetes
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Association, 2013; Committee for Medicinal Products for Human Use, 2012). Hemoglobin is a
protein that binds with glucose and helps carry oxygen from the lungs to the rest of the body.
The more glucose in the blood, the more hemoglobin that attaches to it. The HbA1c test
measures the percentage of hemoglobin with attached glucose. In general, the American Diabetes
Association recommends a target HbA1c of less than 7% for adults (American Diabetes
Association, 2019a) and less than 7.5% for children and adolescents (American Diabetes
Association, 2019b). HbA1c in these ranges indicates good glycemic control, whereas higher
HbA1c indicates poorer glycemic control.
Intense monitoring of blood glucose levels can help health care providers and people with
diabetes determine appropriate insulin therapy (Benjamin, 2002; Canadian Agency for Drugs and
Technologies in Health, 2014; Dungan & Verma, 2000). There are several types of insulin, and
they vary based on onset, peak time, and duration (American Diabetes Association, 2004).
Insulin is often administered via multiple daily injections into the subcutaneous tissue (American
Diabetes Association, 2004). Alternately, insulin pumps deliver short-acting insulin continuously
via a cannula inserted subcutaneously for two to three days at a time (Diabetes.co.uk, 2019;
Didangelos & Iliadis, 2011).

Negative Outcomes of Type 1 Diabetes
Youth with T1D are at risk for acute and chronic complications (Hamman et al., 2014).
Acute complications include DKA and severe hypoglycemia, both of which can be lethal in
severe cases (Rewers et al., 2002). As discussed, DKA occurs when there is insufficient insulin
in the body and may be associated with symptoms such as dehydration, shortness of breath,
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nausea/vomiting/abdominal pain, confusion, loss of consciousness, and even death. Conversely,
severe hypoglycemia occurs in the presence of excessive insulin. Severe hypoglycemia may
result in loss of consciousness, seizure, or death.
The adverse long-term complications associated with T1D are well-established and
include retinopathy, nephropathy, neuropathy, and cardiovascular disease (Nathan, 1993; White,
2015). Both blood glucose variability and duration of disease are associated with long-term
complications (White, 2015). Thus, due to longer disease duration, young children are at
increased risk for long-term complications (Imperatore et al., 2012). Another concerning
complication of T1D is its potential negative effect on the brain and cognitive functioning (Ryan
et al., 2016). The mechanisms are unclear, but there is some evidence to suggest that T1D is
associated with reductions in intelligence, academic achievement, attention, psychomotor speed,
and executive functioning. Risk factors include chronically elevated blood glucose levels and
earlier age of onset. Young children appear to be at increased risk of negative neurocognitive
consequences. Indeed, diagnosis prior to age 7 is the strongest risk factor for neurocognitive
dysfunction among those with T1D (Ryan et al., 2016).
Another negative aspect of T1D is the economic burden, which researchers have
estimated to be approximately $14.9 billion in the US annually – $10.5 billion for medical costs
and $4.4 billion for indirect costs (Dall et al., 2009). The estimated average annual cost per case
of T1D in the US is $14,856 (Dall et al., 2010).

5

Unique Challenges of Managing Type 1 Diabetes in Young Children
T1D requires lifelong adherence to a complex and time-consuming treatment regimen of
blood glucose monitoring and insulin administration in order to maintain tight glycemic control
to prevent or delay life-threatening complications. Clearly, T1D is a demanding disease at any
age, but there are unique challenges in managing T1D in young children. Streisand and
Monaghan (2014) identified and described specific developmental, psychosocial, and
physiological challenges in managing T1D in children younger than age 6.
Developmentally, children in this age group exhibit rapid physical growth, erratic eating,
and bursts of physical activity, which may lead to a need for even more intensive blood glucose
checking, nutrition monitoring, and insulin adjustment (Streisand & Monaghan, 2014). It may
also be difficult to get children to remain still for blood glucose checks, injections, and
CGM/pump site changes. Additionally, young children are typically just learning to verbalize
thoughts and feelings and may experience difficulty recognizing and communicating symptoms
of high and low blood glucose levels (Streisand & Monaghan, 2014). Cognitively, young
children engage in concrete thinking that may make it difficult for them to understand why they
need to engage in diabetes-specific behaviors. Socially, young children may begin to spend more
time away from parents. Thus, parents need to teach other caregivers how to recognize diabetesspecific symptoms and train them in diabetes management. Finally, young children’s emotional
and behavioral development may include temper tantrums, striving for autonomy, and/or the
emergence of specific fears that may further complicate parents’ ability to manage the disease
(Streisand & Monaghan, 2014).
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Sullivan-Bolyai et al. (2003) coined the phrase “constant vigilance” to describe the
significant stress, fears, and burden of responsibility associated with caring for a young child
with T1D. In a study examining the perceptions of parenting young children with T1D,
Smaldone and Ritholz (2011) identified three specific themes. First, the diagnostic experience
was often associated with many frustrations, fears, and doubts. In many cases, the actual
diagnosis was delayed, and parents often believed that their concerns were minimized or
dismissed. Many children under age 6 present as critically ill (in DKA) at time of diagnosis
(Quinn et al., 2006). Many parents reported feeling shock and distress related to the abrupt
hospitalization, while simultaneously feeling anxious about managing their child’s disease on
their own when discharged. Second, in learning to adapt to the demands of their child’s diabetes,
parents described feeling overwhelmed and filled with self-doubt. They also described feeling
very isolated – they explained that many people in the family’s social support system did not or
could not understand diabetes care and were often fearful of caring for the child. Third,
negotiating developmental transitions was especially challenging for parents of young children
with T1D. They struggled to find the balance between fostering self-efficacy and ensuring their
child’s safety as their child faced normative milestones and events, such as school, fieldtrips,
sports, and sleepovers.
The burden of caring for their child’s T1D may negatively impact parents’ functioning in
many domains, including sleep quality, job performance, and social life (Streisand & Monaghan,
2014). It is not difficult to see how caring for a child with T1D may affect the caregivers’
psychological functioning and quality of life. Indeed, parents of children with T1D report greater
levels of distress and problems with parenting than parents of healthy children, and some report
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clinically significant symptoms of depression, anxiety, and post-traumatic stress (Jaser et al.,
2009; Whittemore et al., 2012). In a study of caregiver stress and coping among parents of
children with T1D, Stallwood (2005) reported a negative association between stress and the age
of the child, suggesting that parents of young children with T1D may be especially vulnerable to
stress.
Finally, there are at least two physiological factors that complicate the management of
T1D in young children. The first relates to a phenomenon in diabetes known as “the honeymoon
phase.” After T1D is diagnosed, existing beta cells may continue to produce some insulin for a
period of time, but the quantity and duration of insulin produced is unpredictable. Thus, this
period necessitates extra blood glucose monitoring and constant insulin adjustments, at a time
that families are still adjusting to diagnosis and learning the treatment regimen. One study
reported that approximately 69% of children experience a honeymoon phase (Abdul‐Rasoul et
al., 2006). The second factor is hypoglycemia unawareness, which refers to the inability to
recognize the signs and symptoms of hypoglycemia. This is dangerous because it may prevent
the individual with diabetes and their caregivers from taking steps to correct the hypoglycemic
episode before severe hypoglycemia occurs. Ly et al. (2009) reported that 29% of children and
adolescents have impaired hypoglycemia awareness and that this rate is even greater among
children younger than age 6. For this and many other reasons that will be further examined, fear
of hypoglycemia is a significant issue among parents of young children with T1D.
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Hypoglycemia
Rather than a negative consequence of diabetes, hypoglycemia is better understood as a
negative consequence of insulin therapy (White, 2015). Hypoglycemic episodes are typically
triggered by an imbalance of insulin, food intake, and physical activity (Gonder-Frederick et al.,
2011). Early signs and symptoms of hypoglycemia include shakiness, sweating, rapid heartbeat,
hunger, and irritability. These are termed neurogenic symptoms, and they occur because low
blood glucose levels trigger an autonomic response (American Diabetes Association Workgroup
on Hypoglycemia, 2005; White, 2015). A continued state of hypoglycemia eventually leads to
reduced availability of glucose to the brain, which triggers neuroglycopenic symptoms that may
include sleepiness, lethargy, confusion, loss of consciousness, seizure, coma, and death
(American Diabetes Association Workgroup on Hypoglycemia, 2005; White, 2015). The
presence of neurogenic symptoms is often referred to as mild hypoglycemia, and the presence of
neuroglycopenic symptoms is often referred to as severe hypoglycemia. The American Diabetes
Association Workgroup on Hypoglycemia (2005) has emphasized that severe hypoglycemia
requires the assistance of another person to intervene and administer emergency glucose and/or
other resuscitative actions, but as most children require assistance to correct even mild
hypoglycemia, this recommendation may be inaccurate when considering a young population.
Similar to many other pediatric diabetes researchers, Rewers et al. (2002) defined severe
hypoglycemia as a hypoglycemic episode resulting in loss of consciousness, seizure, hospital
admission, or emergency department visit. They reported the incidence of severe hypoglycemia
as 19 per 100 person-years in a large cohort of children, adolescents, and young adults, ages 0–
19, located in Denver, Colorado. Consistent with many other reports (see Cengiz et al., 2013;
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Davis et al., 1998; Lteif & Schwenk, 1999; Mortensen et al., 1997), they found that severe
hypoglycemia was more common in younger children. In 1993, the Diabetes Control and
Complications Trial (DCCT) Research Group published an influential paper demonstrating that
intensive therapy with the goal of keeping blood glucose levels close to the normal range may
delay the onset and slow the progression of diabetes-related complications, but was associated
with increased risk of severe hypoglycemia (The DCCT Research Group, 1993).
However, there is evidence that the risk of severe hypoglycemia has reduced significantly
in recent years. O’Connell et al. (2011) reported evidence that the rates of severe hypoglycemia
have reduced in children and adolescents and speculated that these reductions may be due to
improved treatment regimens, including more intensive glucose monitoring, new insulin
regimens, and improved management guidelines. Technological advances may also contribute to
reduced rates of severe hypoglycemia (Prahalad et al., 2018). A large cohort study conducted in
Germany and Austria concluded that the risk of severe hypoglycemia associated with low
HbA1c has decreased substantially in children and adolescents with T1D in the last decade
(Karges et al., 2014). Nonetheless, hypoglycemia remains the most common acute complication
of T1D and the risk of hypoglycemia presents a significant barrier to obtaining optimal glycemic
control (Ly et al., 2014). Considering that mild hypoglycemia is often neither recognized nor
reported, the incidence of mild hypoglycemia is unknown (Ly et al., 2014); yet, both mild and
severe hypoglycemic events are associated with substantial healthcare costs and reduced quality
of life (Fidler et al., 2011; Foos et al., 2015).

10

Fear of Hypoglycemia
In summary, hypoglycemia is a common, but serious, complication of T1D management.
There is no doubt that severe hypoglycemia can be fatal (Cryer, 2011, 2012). Some individuals
may experience aversive physical symptoms that signal their hypoglycemic state, but those with
impaired hypoglycemia awareness may not. Hypoglycemic unawareness is common in young
children with T1D (Ly et al., 2009) as they may not yet have developed the cognitive and
linguistic abilities necessary to recognize and communicate their symptoms (Streisand &
Monaghan, 2014). In young children, signs and symptoms of hypoglycemia may also include
behavioral changes, including irritability, agitation, quietness, and tantrums (Ly et al., 2014), that
may be difficult to differentiate from normal, developmentally appropriate behaviors. To further
complicate matters, recent episodes of hypoglycemia may lead to hypoglycemic unawareness,
representing a viscous cycle of recurrent hypoglycemia (American Diabetes Association
Workgroup on Hypoglycemia, 2005). Clearly, hypoglycemia represents an unpleasant, if not
frightening prospect, especially for parents of young children with T1D. For some time, diabetes
researchers have been interested in how fear of hypoglycemia (FOH) may impact diabetes care.
Accordingly, many researchers (e.g., Clarke et al., 1998; Cox et al., 1987; Gonder-Frederick et
al., 1997, 2011; Green et al., 1990; Kamps et al., 2005; Martyn-Nemeth et al., 2017; Patton et al.,
2007, 2008, 2017) have endeavored to operationalize FOH in order to study it more effectively.
The Hypoglycemic Fear Survey (HFS) was the first instrument developed to quantify
FOH in individuals with T1D (Cox et al., 1987), and it remains a widely used measure of
hypoglycemic fear (Barnard et al., 2010; Driscoll et al., 2016; Wild et al., 2007). To generate
initial items, researchers solicited input from both diabetes health care providers and adults with

11

T1D, and then divided the items into two categories: behavioral avoidance of hypoglycemia
(Behavior) and affective fear of hypoglycemia (Worry). An updated version of the HFS, the
HFS-II, was published in 2011, and factor analyses and item-response theory supported the use
of the two subscales (Gonder-Frederick et al., 2011). Over time, the HFS has been adapted for
various populations, including children (Green et al., 1990), parents (Clarke et al., 1998), and
spouses of individuals with diabetes (Gonder-Frederick et al., 1997).
The first adaption of HFS for use with parents (HFS-P) and was administered to mothers
of children under age 12 with T1D (Clarke et al., 1998). These researchers found that maternal
scores were greater than scores for adults with T1D, indicating that mothers had greater fear of
their children experiencing hypoglycemia than did adults who had diabetes (and had probably
had more actual experience with hypoglycemia). In 2007, the HFS-P was further modified to be
specific to issues of parents of young children (HFS-PYC; Patton et al., 2007). This research
team initially administered the survey to 24 families of children ages 2–8 with T1D, all of whom
were receiving insulin via pumps. In 2008, the HFS-PYC was administered to a larger sample of
parents of young children, including both mothers (n = 81) and fathers (n = 64) (Patton et al.,
2008). In 2017, the HFS-PYC was administered to a sample of 116 parents of young children
ages 1–7 using insulin pumps, and confirmatory factor analysis confirmed the measure’s original
two-factor structure in this population (Patton et al., 2017).
Another measure for assessing FOH is the Children’s Hypoglycemia Index (CHI), a selfreport measure designed specifically for use with children with T1D (Kamps et al., 2005). The
CHI was administered to 109 children ages 8–16 with T1D who attended a diabetes summer
camp. With this sample, the CHI demonstrated adequate psychometric properties, including
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support for three subscales: general fears related to hypoglycemia and its consequences, fears in
specific situations, and behaviors to avoid/prevent hypoglycemia. One item with no face validity
and low total item correlation was excluded in the second version of the measure, which was also
administered to children ages 8-16 (CHI-R or CHI-2; Jurgen et al., 2020; Kamps & Varela,
2010).
Several factors may contribute to the development of FOH. Among adults with diabetes,
previous experience with hypoglycemia and actual risk of hypoglycemia are two such factors
(Wild et al., 2007). State and trait anxiety are also associated with FOH, but the direction of this
relation is not clear – it is possible that the relation is bidirectional (Wild et al., 2007). Among
parents of children with T1D, parent report of the child experiencing severe hypoglycemic
episodes is a predictor of the parent’s FOH (Driscoll et al., 2016). Specifically, mothers of
children who have experienced loss of consciousness due to hypoglycemia have more FOH than
mothers of children who have not (Clarke et al., 1998). Higher maternal anxiety is also
associated with greater FOH (Jaser et al., 2009), but once again, the direction of this relation has
not been well-established.
Pierce et al. (2017) developed and proposed a conceptual model of T1D in young
children that incorporates both parent and child influences on management and outcomes. They
postulated that parental FOH is one of many factors of parental coping that are important to
understanding T1D in young children. Broadly, the model suggests that individual parent
characteristics (such as sociodemographic factors, social support, parenting style, and preexisting psychiatric history) influence parental affective, behavioral, and cognitive coping.
Factors that reflect parental coping include parents’ psychological functioning and adjustment
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post-diagnosis, level of sleep disruption, and FOH. Parental coping may directly influence T1D
management behaviors (including self-care, adherence, problem-solving skills, and
communication with the child’s diabetes team), which may, in turn, influence T1D outcomes
(such as HbA1c, episodes of severe hypoglycemia, and quality of life). Individual child
characteristics, such as temperament, age, and development, fit into the model by mediating and
moderating the relations between parental coping and T1D management behaviors. Focusing on
FOH, the model posits that parental FOH impacts T1D management behaviors directly, and
indirectly affects T1D outcomes. Many researchers (e.g., Clarke et al., 1998; Freckleton et al.,
2014; Gonder-Frederick et al., 2011; Gonder‐Frederick et al., 2006; Haugstvedt et al., 2010;
Hawkes et al., 2014; Johnson et al., 2013; Pate et al., 2016; Patton et al., 2007, 2008, 2017;
Shepard et al., 2014; Van Name et al., 2018; Viaene et al., 2017) have examined these specific
relations, but findings have been inconsistent.

Fear of hypoglycemia & glycemic control
Pierce et al.’s (2017) model includes several factors that may be used to define T1D
outcomes (i.e., HbA1c, episodes of severe hypoglycemia, and quality of life), but the most
commonly studied T1D outcome is glycemic control. The most common measure of glycemic
control, by far, is HbA1c, a measure that reflects mean blood glucose level over the past two to
three months (Agiostratidou et al., 2017; Canadian Agency for Drugs and Technologies in
Health, 2014; Committee for Medicinal Products for Human Use, 2012; U.S. Department of
Health and Human Services Food and Drug Administration, 2008). Another variable that has
been used to measure glycemic control is the average daily blood glucose reading, that can be
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self-reported after finger-sticks or calculated by downloading data from CGMs, which record
blood glucose levels every five to 15 minutes (Dungan & Verma, 2000). Numerous studies have
examined the relation between parental FOH and glycemic control, and results have also been
inconsistent.
Some studies have found that greater parental FOH is associated with poorer glycemic
control. In a sample of parents of children ages 2–8 using pumps, Patton et al. (2007) reported
positive correlations between parental FOH and average daily blood glucose levels, and between
the HFS Behavior Subscale and HbA1c. In a study with mothers of children under age 12, Clarke
et al. (1998) reported a positive correlation between parental FOH and HbA1c. Freckleton et al.
(2014) reported a positive correlation between the HFS Behavior Subscale and blood glucose
levels recorded in a diary by the mothers of children under age 13. In a sample of parents of
children ages 1–15, Haugstveld et al. (2010) found a significant positive relation between the
HFS Worry Subscale and HbA1c. In a sample of parents of children up to age 18, Hawkes et al.
(2014) found that parents of children with HbA1c less than 7.5% (i.e., close to or within target
range) had less FOH. Although the sample did not include young children, Pate et al. (2016) also
reported positive correlations between parental FOH and HbA1c, and between the HFS Worry
Subscale and HbA1c, in a sample of parents of children ages 7–17.
The specific mechanisms involved in this association between parental FOH and
glycemic control have not been investigated empirically, but many researchers have suggested
that parents’ fear may lead them to engage in hypoglycemia avoidance behaviors, such as
administering too little insulin or encouraging their child to overeat, which would result in
hyperglycemia (Barnard et al., 2010; Freckleton et al., 2014; Gonder-Frederick et al., 2011;
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Marrero et al., 1997; Wild et al., 2007). One pathway that has received empirical support is that
parental FOH leads to parenting stress, which leads to poorer glycemic control (Viaene et al.,
2017).
Some studies have found that greater parental FOH is associated with better glycemic
control. In a sample of parents of children ages 2–7 using pumps, Patton et al. (2017) reported a
negative correlation between the HFS Worry Subscale and average daily blood glucose levels.
Additionally, they found that the HFS Worry Subscale was correlated positively with the
percentage of blood glucose readings in target range. Although the sample did not include young
children, Gonder-Frederick et al. (2011) also found that greater parental FOH was associated
with better glycemic control in a sample of parents of children ages 6–18. Specifically, the HFS
Behavior Subscale was correlated negatively with HbA1c. Speculating that the relation between
parental FOH and glycemic control may not be linear, they also compared parents who scored in
the highest and lowest quartiles of the HFS, and they found that parents with high FOH had
children with lower HbA1c compared to parents with low FOH.
Their sample also did not include young children, but Shepard et al. (2014) also divided
parents into groups based on their level of FOH and examined differences between the highest
and lowest tertiles. They utilized an aggregated sample of parents of children ages 6–18. The
main aim of their study was to investigate the underlying factor structure of the HFS for parents
and, using exploratory factor analysis, they found that a four-factor solution appeared to be the
best fit. They determined that each subscale consisted of two factors. The Behavior Subscale
factors included: (1) behaviors used to keep blood glucose high to prevent hypoglycemia
(Maintain High BG) and (2) other actions to avoid hypoglycemia (Avoidance). The Worry
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Subscale factors included: (1) concerns about helplessness (Helplessness) and (2) negative social
consequences associated with hypoglycemia (Social Consequences). They found that parents
who scored in the highest tertile of the Avoidance factor (in the Behavior Subscale) had children
with significantly lower mean HbA1c values compared to parents who scored in the lowest
tertile of the Avoidance factor. No other significant differences were found.
Once again, the specific mechanisms involved in this association between parental FOH
and glycemic control have not been investigated empirically, but it is possible that parents may
become more fearful of hypoglycemia as their child’s blood glucose levels approach the
hypoglycemic range. In line with this hypothesis, Irvine et al. (1991) argued that actual risk of
hypoglycemia should be considered when evaluating FOH, as high fear when there is high risk
of hypoglycemia may be adaptive. Alternately, it has been suggested that higher scores on the
HFS Behavior Subscale, in particular, may reflect a parent that is more engaged in their child’s
diabetes management overall, which may result in better glycemic control (Gonder-Frederick et
al., 2011).
Some studies have found no significant associations between parental FOH and glycemic
control. There have been several studies consisting of samples of parents of young children
exclusively that have reported no relations. Patton et al. (2008) found no significant relation
between parental FOH and either HbA1c or average daily blood glucose levels. Additionally,
Van Name et al. (2018) and Patton et al. (2007) both reported no significant relation between the
HFS Worry Subscale and HbA1c. Finally, Patton et al. (2017) reported no significant relation
between the HFS Behavior Subscale and average daily blood glucose levels. Although
Freckleton et al. (2014) had noted a significant positive relation between the HFS Behavior
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Subscale and daily measures of blood glucose levels, they found no significant relations between
the HFS Worry Subscale and either daily measures of blood glucose levels or HbA1c in their
sample of mothers of children under age 13. In samples of parents of children ages 2–18,
Johnson et al. (2013) and Viane et al. (2017) both reported no significant association between
parental FOH and HbA1c. Although they did not include young children in their samples,
Gonder-Frederick et al. (2006) and Pate et al. (2016) found no significant relation between
HbA1c and parental FOH and the HFS Behavior Subscale, respectively, in their samples of
parents of children and adolescents. Shepard et al.’s (2014) study, whose sample included
parents of children ages 6–18, found no significant relations between any of the four factors they
identified in the HFS and any measures of glycemic control, except for the previously noted
association between higher Avoidance factor scores and lower mean HbA1c values.
One possible explanation for these inconsistencies is that the relation between parental
FOH and glycemic control is nonlinear. When Cox et al. (1987) published the original version of
the HFS, they argued that excessive FOH may cause poor adherence and hypoglycemia
avoidance behaviors, while too little fear may reflect a general indifference toward
hypoglycemia and may lead to inappropriate denial or disregard of the early warning signs of
hypoglycemia. Since then, many researchers have acknowledged theoretically that a moderate
level of parental FOH may be optimal (Driscoll et al., 2016; Gonder‐Frederick et al., 2006;
Patton et al., 2007; Pierce et al., 2017); yet this hypothesis has not been examined empirically.
Gonder-Frederick et al. (2011) alluded to the possibility of a nonlinear relation, yet in their
analyses, they compared the highest and the lowest quartiles of parental FOH, which would not
allow examination of the impact of moderate FOH. In order to test the hypothesis that moderate
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levels of parental FOH may be associated with better glycemic control in young children, the full
range would need to be examined.

Adherence as a possible mechanism
Adherence, in the context of chronic disease, refers to the extent to which a person’s (or
caregiver’s) behaviors are consistent with health care recommendations (Dunbar-Jacob &
Mortimer-Stephens, 2001; Haynes, 1979; Quittner et al., 2008). In diabetes, adherence is
associated with better glycemic control (Asche et al., 2011). Fundamentally, Cox et al.’s (1987)
argument stated that high fear leads to poor adherence, which leads to poor glycemic control; and
low fear leads to poor adherence, which leads to poor glycemic control. Similarly, Pierce et al.’s
(2017) model predicted that T1D management behaviors would mediate the relation between
parental coping and T1D outcomes; or, more specifically, adherence would mediate the relation
between parental FOH and glycemic control.
Nearly all of the studies that have reported a significant association between parental
FOH and glycemic control have referenced adherence as the mechanism of action in this
relation, even if they have not specifically named it as adherence. For example, Patton et al.
(2007) concluded that high levels of FOH may lead parents to engage in “poorer coping
strategies, such as administering lower doses of insulin, feeding children without administering
insulin, or overtreating episodes of low blood glucose levels” (p. 367), which may, in turn, lead
to hyperglycemia. However, without empirical support, the nature of these relations remains
speculative. Accordingly, many researchers have called for more research in this area (Barnard et
al., 2010; Gonder-Frederick et al., 2011; Gonder‐Frederick et al., 2006). No identified studies
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have examined this mediation using parental FOH, but one study to date has empirically tested
this mediation using children’s self-reported FOH. Among participants ages 8–20, Jurgen et al.
(2020) found that the indirect effect of children’s FOH on HbA1c through adherence was
marginally significant (p < .10). While they had hypothesized that greater FOH would be
associated with poorer adherence and poorer glycemic control, results indicated that lower FOH
was associated with poorer adherence and poorer glycemic control.

Rationale for Study
T1D is a disease that requires adherence to a strict treatment regimen; among young
children with T1D, this burden typically falls on parents. While simultaneously managing the
unique developmental, psychosocial, and physiological challenges present in this age group,
parents must maintain tight glycemic control to delay or prevent serious complications from
occurring. One of the acute risks of T1D is hypoglycemia, which, when severe, may result in the
loss of consciousness, seizure, or even death. Parental FOH may have clinical implications for
diabetes management in young children.
There have been many studies examining FOH, but very few have focused on parents of
young children, specifically. The research that does exist for this population has been
inconsistent. Some studies have found that greater parental FOH is associated with poorer
glycemic control; some studies have found that greater parental FOH is associated with better
glycemic control; and some studies have found no significant associations between parental FOH
and glycemic control. One possible explanation for these inconsistencies is that this relation is
not linear. Specifically, it is possible that a moderate level of fear may be associated with better
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glycemic control than excessive or suppressed fear. This has been suggested theoretically, but it
has not been examined empirically. Similarly, adherence has been offered as a possible
mechanism explaining this relation, but this has also not been investigated empirically as a
nonlinear relationship, nor among parents of young children, specifically. Hypoglycemia is a
common and potentially serious complication among young children with T1D, and low levels of
parental FOH may reflect limited understanding or concern about hypoglycemia, which may be
associated with poor adherence and result in poor glycemic control. High levels of parental FOH
may spur the parent to engage in hypoglycemia avoidance behaviors, which may also lead to
poor glycemic control. Conversely, moderate levels of FOH may represent an adaptive and
reasonable amount of fear, which may lead to improved adherence and better glycemic control.
The aims of this study were to explore the relations among parental FOH, adherence, and
glycemic control, using Pierce et al.’s (2017) model of T1D in young children as a conceptual
and theoretical guide. At a time when the incidence of T1D among young children is increasing,
it is especially important to improve understanding of the barriers and facilitators to achieving
good glycemic control in this population. Therefore, it was hypothesized that:
1) There would be a quadratic relation between parental FOH and glycemic control,
such that parents with high and low levels of fear, as measured by the Hypoglycemia
Fear Survey – Parents of Young Children, would have children with poorer glycemic
control, as measured by the child’s HbA1c, relative to parents with moderate levels of
fear.
2) Similarly, there would be a quadratic relation between parental FOH and adherence,
such that parents with high and low levels of fear would have poorer adherence, as
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measured by the Diabetes Self-Management Profile – Self Report Parent Form,
relative to parents with moderate levels of fear.
3) Finally, adherence would mediate the relation between parental FOH and glycemic
control.

22

METHODS
Participants
This study utilized baseline data of parents of children diagnosed with T1D before age 6
who were enrolled in a randomized clinical trial assessing the effectiveness of an online coping
intervention for parents of young children with T1D. All procedures of the original study were
approved by the Nemours Institutional Review Board. The procedures of the present study were
reviewed by the University of Central Florida Institutional Review Board and determined to not
be human subjects research. Therefore, the present study was exempt from review.
Recruitment methods included e-mails sent to eligible parents of patients followed within
a children’s health system with sites in Florida and Delaware. Additionally, online
announcements were shared on diabetes-focused websites, blogs, and social media groups, as
well as with T1D clinicians in North America. Participants were eligible if they: (a) were the
parent or legal guardian of a child with T1D under age 6 at the time of informed consent, (b) had
access to the internet several times per week, (c) lived in the U.S. during the study, and (d) could
read and write in English.
A total of 172 parents submitted information. Of these, 158 identified as mothers (157
mothers and 1 adoptive mother) and 14 identified as fathers (13 fathers and 1 stepfather). Seven
children had two parents respond. All seven of these sets of parents included one parent that
identified as mother and one that identified as father. It was not possible to determine which of
these parents were the primary caregivers, as it was assumed that each parent completing the
form was the primary caregiver. Given this limitation, the overall low number of responses from
fathers, and reports that mothers and fathers differ significantly in their fear of hypoglycemia
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(Haugstvedt et al., 2010; Patton et al., 2008), an a priori decision was made to exclude fathers
from the main analyses. HFS-PYC scores for mothers (M = 77.15, SD = 18.82) and fathers (M =
67.93, SD = 17.81) were comparable to previously published HFS-PYC scores obtained from
mothers (M = 75.0, SD = 17.2) and fathers (M = 66.5, SD = 18.0) (Patton et al., 2008).
There were other exclusions. One participant had an HbA1c value (HbA1c = 15.4) that
was greater than four standard deviations above the mean. Given that results of regression
analyses can be significantly impacted by outliers (Stevens, 1984), this case was excluded from
analyses. Lastly, due to missing or incomplete data, an additional 14 participants were excluded
from the analyses, yielding a final sample size of 143 (see Figure 1).

Figure 1: Participant Flow Chart
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Procedure
Potential participants received an e-mail or online announcement with information about
the study and a link to an electronic informed consent form. After informed consent was
obtained, participants were directed to an online demographic information form where they
provided demographic information about themselves and their child, along with information
about their child’s diabetes care. Next, participants completed a number of online self-report
measures related to general and diabetes-specific functioning. Participants provided an e-mail
address and other contact information to facilitate continued contact throughout the study and
receive compensation. Participants received $50 for completing baseline measures.

Measures
Demographic characteristics and medical history
Parent, child, and family characteristics were collected through a questionnaire that
included the parent’s and child’s age, gender, ethnicity, race, and country of birth, in addition to
the parent’s educational attainment, occupational category, and household income. Participants
also provided information about the child’s home environment, including the primary language
spoken. Regarding medical history, participants provided duration of TID diagnosis, type of
insulin delivery, use of a CGM, location of diabetes care, number of HbA1c tests in past 6
months, and health insurance coverage.
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Anxiety
The Brief Symptom Inventory 18 (BSI 18; Derogatis, 2001) measures psychological
distress. This measure is a briefer version of the 53-item Brief Symptom Inventory (BSI;
Derogatis & Melisaratos, 1983), which is a shorter version of the Symptom Checklist-90Revised (SCL-90-R; Derogatis, 1975). The BSI 18 is an 18-item questionnaire that yields a
global severity index and three symptom scales: somatization, depression, and anxiety.
Respondents are asked to rate how much a problem (e.g., “faintness or dizziness,” “feeling no
interest in things,” “nervousness or shakiness inside”) has distressed or bothered them during the
past week using a 5-point Likert scale (0 = not at all to 4 = extremely). Possible range of scores
on the global severity index is 0 – 72, and possible range of scores for each symptom subscale is
0 – 24. Higher scores indicate greater distress. The anxiety symptom scale was utilized to
measure parents’ anxiety.
The BSI 18 has demonstrated acceptable to good internal consistency reliability. Derived
from a community sample, alpha coefficients were .89 for the global severity index and .74, .84,
and .79 for the three symptom scales: somatization, depression, and anxiety, respectively
(Derogatis, 2001). Test-retest reliability statistics were not reported, but the authors estimated .90
for the global severity index, and a range of .68 to .84 for the symptom scales (Boothroyd &
Hanson, 2003). Strong correlations were reported between the BSI 18 and corresponding scores
on the SCL-90-R – .93 for the global severity index, and .91, .93, and .96 for the three symptom
scales: somatization, depression, and anxiety, respectively.
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Fear of hypoglycemia
The Hypoglycemia Fear Survey – Parents of Young Children (HFS-PYC; Patton et al.,
2007, 2008) was used to measure parental FOH. This measure was modified from the
Hypoglycemia Fear Survey – Parent (HFS-P; Clarke et al., 1998), which was an adaption of the
original Hypoglycemia Fear Survey (HFS; Cox et al., 1987), to be specific to the issues of
parents of young children. The 26-items consists of two subscales: the Behavior Subscale, which
assesses parents’ behaviors related to preventing hypoglycemia, and the Worry Subscale, which
assesses parents’ worries about the possibility of hypoglycemia. Parents are asked to rate how
often each item is true for them on a 5-point Likert scale (1 = never to 5 = very often); for
example, an item on the Behavior Subscale states, “Feed my child large snacks at bedtime,” and
an item on the Worry Subscale states, “Not recognizing that my child is having a hypoglycemic
event.” Possible range of scores is 26 – 130, and higher scores indicate greater fear of
hypoglycemia.
The HFS-PYC has demonstrated internal consistency and good test-retest reliability
among parents of children ages 2–8 in two separate studies (Patton et al., 2007, 2008). In a
sample of 24 families with children using insulin pumps, Cronbach’s alpha coefficient was .86
for the complete measure, .62 for the Behavior subscale, and .89 for the Worry subscale. The 2week test-retest reliability was .91, .73, and .91, for the Total Score, Behavior Subscale, and
Worry Subscale, respectively (Patton et al., 2007). In a sample of 81 mothers and 64 fathers,
Cronbach’s alpha coefficient was .90, .70, and .93 for mothers, and .92, .74, and .93 for fathers,
for the Total Score, Behavior Subscale, and Worry Subscale, respectively; while the 2-week test-
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retest reliability was .81, .49, .82 for mothers (Patton et al., 2008). Test-retest reliability was not
reported for fathers.

Glycemic control
The child’s HbA1c serves as the measure for glycemic control. HbA1c reflects the mean
blood glucose level over the past two to three months and is a well-validated and widelyaccepted outcome measure in diabetes-related studies (Agiostratidou et al., 2017; Canadian
Agency for Drugs and Technologies in Health, 2014; Committee for Medicinal Products for
Human Use, 2012; U.S. Department of Health and Human Services Food and Drug
Administration, 2008). When feasible, the most recent HbA1c lab results were retrieved from the
child’s medical record. This was possible for the participants who were followed within the
Nemours healthcare system. For those outside of the Nemours healthcare system, HbA1c lab
results were obtained via dried blood spots. Dried blood spot testing is a procedure in which a
blood sample is obtained from a finger-stick, placed on paper, and returned to a laboratory for
analysis. Dried blood spots can be collected by non-professionals in non-clinical settings, and
they are acceptable for measuring HbA1c (Lacher et al., 2013). Participants were mailed
materials and instructions, including return instructions for the dried blood spot test. Higher
HbA1c indicates poorer glycemic control.
Given the dual method of HbA1c measurements, an independent-samples t-test was
conducted to compare HbA1c values obtained via dried blood spots and HbA1c values retrieved
from the medical record. There was no significant difference between the HbA1c values obtained
via dried blood (n = 108, M = 7.75, SD = 1.14, range = 5.2 – 10.7) and HbA1c values retrieved
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from the medical record (n = 35, M = 7.78, SD = 1.17, range = 5.4 – 9.9); t(141) = -0.11, p =
0.913.

Adherence
Adherence was measured using the Diabetes Self-Management Profile – Self Report
(DSMP-SR) Parent Form, which quantifies diabetes self-management behaviors (Buckloh et al.,
2010; Wysocki et al., 2012). The DSMP-SR is a 24-item questionnaire adapted from the
previously validated structured interview assessing T1D adherence, the Diabetes SelfManagement Profile (DSMP; Harris et al., 2000). There are two separate forms, “conventional”
and “flexible.” The conventional version is for patients on conventional regimens, in which
individuals inject premixed insulin or insulin doses using a sliding scale based on their blood
glucose level and follow an individualized diet plan with a fixed amount of carbohydrates. The
flexible version is for patients on flexible regimens, where their insulin dose is determined by
using a formula based on blood glucose readings and anticipated carbohydrate intake. On both
versions, parents are asked to select responses that most accurately reflect the child’s diabetes
care over the previous 3-month period. For example, one item states, “People take care of low
blood sugars in many different ways. What do you or your child usually do to treat your child’s
low blood sugars in the past 3 months?” Parents can select one of the following responses:
“Child has not had a low blood sugar in the past 3 months,” “Careful to quickly take the
prescribed amount of carbs and check the blood sugar after 10 minutes,” “Take prescribed
amount of carbs but does not check blood sugar afterwards,” “Take carbs (not the prescribed
amount) without considering how much,” “Continue taking carbs until symptoms go away,” or
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“Wait until a better time to treat the low blood sugar.” Scores range from 0 – 86. Higher scores
reflect greater adherence. The response scoring for both the conventional and flexible forms is
identical, so the scores were combined for a single DSMP-SR variable.
The DSMP-SR has demonstrated good psychometric properties (Wysocki et al., 2012). In
a sample of parents of children ages 8–17 with T1D, the internal consistency (Cronbach’s alpha
coefficient) of the Parent Form was .80. Additionally, the Parent Form correlated significantly
with HbA1c (r = .46), as well as the PedsQL diabetes module, a measure of diabetes-related
quality of life (r = .47), and the revised diabetes family conflict scale, a measure of T1D-related
family conflict (r = .30). This measure, however, has not been validated among parents of young
children, specifically.

Power Analysis
An a priori power analysis was run using the G*Power computer program (Faul et al.,
2007). Using parameters of .8 power, 0.15 medium effect size, and .05 alpha, and a linear
multiple regression analysis, the calculated sample size for testing the quadratic equations
(hypotheses 1 and 2) was 55 participants.
Fritz and MacKinnon (2007) provide empirically-driven estimates of sample sizes needed
to test mediated effects (hypothesis 3) for .8 power, based on expected sizes of the relations
between the predictor and mediator, and the mediator and the outcome. For this study, the effect
between the predictor (parental FOH; HFS-PYC score) and mediator (adherence; DSMP-SR
Parent Form score) is unknown, but was estimated to be moderate. The effect between the
mediator (adherence; DSMP-SR Parent Form score) and the outcome (child’s glycemic control;
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HbA1c) was found to be moderate in a previous study (Wysocki et al., 2012). The estimated
sample size needed for bias-corrected bootstrap test with a moderate-moderate path is 71
participants. Thus, the sample size of 143 should provide sufficient statistical power to detect
effects for each hypothesis.
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RESULTS
Participant Characteristics
One hundred forty-three parents and children participated in the study and their data was
used in these analyses. For complete demographic information, see Table 1 for parent and family
characteristics and Table 2 for child characteristics. Parents ranged in age from 20–68 years (M =
33.83, SD = 5.74). As previously mentioned, only the responses obtained from mothers were
used in this study. Mothers were predominantly Non-Hispanic (93.7%) and Caucasian (91.5%),
and most were born in the USA (97.2%). Most participants were above average in terms of
educational attainment, occupational category, and household income. The primary language
spoken in the home was predominantly English (97.2%).
Children ranged in age from 1–6 years (M = 3.86, SD = 1.26). There were slightly more
males (53.8%) than females (46.2%). Children, like their parents, were predominantly NonHispanic (89.4%), Caucasian (88.0%), and born in the USA (99.3%). Duration of T1D diagnosis
ranged from 0–64 months (M = 20.20, SD = 14.28). More than half of the children were using
insulin pumps (58.7%) and most were using continuous glucose monitors (CGMs; 87.4%). Most
children (75.5%) were receiving their T1D care outside of Nemours, the healthcare system where
this data was collected, and about half of the children had private health insurance (52.1%). The
number of HbA1c tests in the past 6 months ranged from 0–3 (M = 1.89, SD = 0.64).
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Table 1: Parent and Family Demographic Data
Characteristic
n
Range
Mean (SD) or %
Age (years)
143
20 - 68
33.83 (5.74)
a
Female
143
100
Ethnicity (Non-Hispanic/Hispanic)
134/9
93.7/6.3
Race
Caucasian
130
91.5
African-American
3
2.1
Asian
3
2.1
Multi-racial
3
2.1
Other/Prefer not say
3
2.1
Country of birth (USA/Other)
139/4
97.2/2.8
Educational attainment
HS diploma/GED
14
9.8
Some college/technical school
48
33.6
Bachelor's degree
50
35.0
Advanced degree
31
21.7
Occupational category
Not employed outside of the home
47
35.9
Operational/technical level
29
22.1
Managerial level
33
25.2
Professional level
22
16.8
Household annual income
<$50k
42
29.8
$50k - $99k
54
38.3
$100k - $149k
26
18.4
≥$150k
19
13.5
b
Others in the home (Y/N)
118/25
82.5/17.5
Primary language (English/Other)
139/4
97.2/2.8
Note. Percentages may not add to 100% due to rounding.
a
14 males excluded from analysis. bQuestion stated: "Does anyone else live at home with your
child other than you?"

33

Table 2: Child Demographic Data
Characteristic
n
Age (years)
143
Male/Female
77/66
Ethnicity (Non-Hispanic/Hispanic)
127/15
Race
Caucasian
125
African-American
3
Asian
1
Multi-racial
9
Other/Prefer not say
4
Country of birth (USA/Other)
142/1
Duration of T1D (months)
143
Insulin delivery
Insulin pump
84
Multiple daily injections
57
Conventional
2
Use of continuous glucose monitor (Y/N)
125/18
T1D care provider (Nemours/Not Nemours)
35/108
Number of HbA1c tests in past 6 months
138
Health insurance type
Public/Medicaid
38
Military
13
Private (PPO, HMO, or both)
74
Public/Medicaid and Other/Military/Private
13
Other
4
Note. Percentages may not add to 100% due to rounding.

Range
1-6

Mean (SD) or %
3.86 (1.26)
53.8/46.2
89.4/10.6

0 - 64

88.0
2.1
0.7
6.3
2.8
99.3/0.7
20.20 (14.28)

0-3

58.7
39.9
1.4
87.4/12.6
24.5/75.5
1.89 (0.64)
26.8
9.2
52.1
9.1
2.8

Main Analyses
All analyses were performed in SPSS (IBM Corp, 2015). Missing values for the BSI 18
and HFS-PYC were replaced with the mean of items answered. DSMP-SR total scores were
adjusted for missing items by: subtracting the maximum number of points for each missing item
from 86 (the greatest possible score); dividing that quantity by 86, yielding a value between 0
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and 1; and, dividing the total score for that participant by this value. Any measures less than 80%
completed were excluded from analyses.
Outliers were identified by examining the distance of each data point from its respective
sample mean. With the exception of one excluded HbA1c value, all data points were within +/- 4
SDs of their sample mean. Assumptions of individual variables underlying multiple regression
analysis were examined (i.e., independence, linearity, normality, homoscedasticity, lack of
multicollinearity) and no significant violations were identified.
Extant literature has reported an association between anxiety and FOH (Clarke et al.,
1998; Wild et al., 2007). Additionally, in their examination of FOH in parents of young children
specifically, Patton et al. (2008) suggested incorporating measures of parents’ level of general
anxiety to aid in understanding HFS-PYC scores. For these reasons, this study examined the
relation between parental anxiety and parental FOH. Results of the Pearson’s correlation
indicated that there was a significant positive association between parental anxiety and parental
FOH, r(140) = .31, p < .001. Thus, parental anxiety was entered into subsequent analyses as a
covariate.
Descriptive statistics for study variables were analyzed. Hypothesis 1 examined the
association between parental FOH (HFS-PYC score) and the child’s glycemic control (HbA1c).
The HFS-PYC variable was mean-centered, and this was utilized as the linear predictor. The
HFS-PYC variable was mean-centered and squared, and this was utilized as the quadratic
predictor. These variables were mean-centered to reduce collinearity between them. The linear
and quadratic terms were entered as predictors of the outcome (HbA1c), using hierarchical
regression. Hypothesis 2 examined the association between parental FOH (HFS-PYC score) and
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adherence (DSMP-SR Parent Form score) in a similar manner. The linear and quadratic terms for
parental FOH were entered as predictors of the outcome (DSMP-SR Parent Form score), using
hierarchical regression.
Finally, hypothesis 3 aimed to examine the possible indirect effect of parental FOH
(HFS-PYC score) on the child’s glycemic control (HbA1c) through adherence (DSMP-SR Parent
Form score). An instantaneous indirect effect analysis was planned using the MEDCURVE
macro (Hayes & Preacher, 2010) developed for SPSS. This approach quantifies the effect of the
predictor on the outcome through the mediator at a specific value of the predictor. Significance
testing was planned by calculating and examining confidence intervals constructed using biascorrected bootstrapping.

Descriptive statistics
Descriptive statistics for study variables are presented in Table 3.

Table 3: Descriptive Statistics
Variable
Range
Mean (SD)
Cronbach’s Alpha
BSI 18 (anxiety)
0 - 21
4.90 (4.68)
.87
HFS-PYC
40 - 117
77.77 (18.58)
.92
HbA1c
5.2 - 10.7
7.76 (1.14)
NA
DSMP-SR
27 - 78
61.08 (10.29)
.76
Note. Cronbach’s alpha for DSMP-SR was calculated using the flexible version of the measure
only. There were too few cases to conduct this analysis for the conventional version.
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Hypothesis 1
Hypothesis 1 posited that there would be a quadratic relation between parental FOH
(HFS-PYC score) and glycemic control (HbA1c), such that parents with high and low levels of
fear would have children with poorer glycemic control relative to parents with moderate levels of
fear. To test hypothesis 1, a hierarchical regression analysis was conducted with HbA1c as the
dependent variable. Parental anxiety was entered in block one to control for general parental
anxiety. Parental FOH (linear) was entered in block two to examine the fit of a linear model.
Parental FOH (squared) was entered in block three to examine the fit of a quadratic model.
Regression statistics are presented in Tables 4 and 5.
The results of the first block hierarchical regression analysis revealed a model that was
not statistically significant, F(1,140) = 2.018, p = .158. The R2 value of .014 associated with this
regression model suggests that parental anxiety accounts for 1.4% of the variance in HbA1c. The
adjusted R2 value, which is a modified version of the R2 value that has been adjusted for the
number of predictors in the model, is 0.007.
The results of the second block hierarchical regression analysis revealed a statistically
significant model, F(2,139) = 3.700, p = .027. The R2 value of .051 associated with this
regression model suggests that parental anxiety and parental FOH (linear) account for 5.1% of
the variance in HbA1c. The adjusted R2 value is .037. The increase of the adjusted R2 value from
the previous model suggests that the addition of parental FOH (linear) improved the model by
more than would be expected by chance. Additionally, the R2 change value of .036 associated
with this regression model suggests that the addition of parental FOH (linear) accounts for an
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additional 3.6% of the variation in HbA1c. The inclusion of parental FOH (linear) produced a
statistically significant increase in variance accounted for in HbA1c, p = .023.
The results of the third block hierarchical regression analysis revealed a model that was
not statistically significant, F(3,138) = 2.668, p = .050. The R2 value of .055 associated with this
regression model suggests that parental anxiety, parental FOH (linear), and parental FOH
(quadratic) account for 5.5% of the variance in HbA1c. The adjusted R2 value is .034. The
decrease of the adjusted R2 value from the previous model suggests that the addition of parental
FOH (quadratic) improved the model by less than expected by chance. The R2 change value of
.004 associated with this regression model suggests that the addition of parental FOH (quadratic)
accounts for an additional 0.4% of the variation in HbA1c. The inclusion of parental FOH
(quadratic) did not produce a statistically significant increase in variance accounted for in
HbA1c, p = .431. Of note, the negative standardized regression coefficient of the quadratic term
(β = -0.07) describes a parabola that opens downward, the opposite direction than hypothesized.
Overall, the results of the analyses did not support the first hypothesis that there would be a
quadratic relation between parental FOH and glycemic control.
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Table 4: Linear Model of Predictors of HbA1c
Regression Coefficients
B
SE B
β

Statistical Significance
t
p

Block 1
(Constant)
7.60
0.14
55.54
< .001***
Parental anxiety
0.03
0.02
0.12
1.42
.158
Block 2
(Constant)
7.68
0.14
55.33
< .001***
Parental anxiety
0.01
0.02
0.06
0.66
.513
Parental FOH (linear)
0.01
0.01
0.20
2.31
.023*
Block 3
(Constant)
7.74
0.16
48.50
< .001***
Parental anxiety
0.02
0.02
0.06
0.70
.484
Parental FOH (linear)
0.01
0.01
0.22
2.42
.017*
Parental FOH (quadratic)
< .001
< .001
-0.07
-0.79
.431
Note. Parental FOH (linear) was mean-centered. Parental FOH (quadratic) is the linear term
squared.
*p < .05. **p < .01. ***p < .001

Table 5: Model Summary of Hierarchical Regression Model with HbA1c as Dependent Variable
Overall Model Fit
2
R
adj R2
F
Block 1
0.014
0.007
2.02
Block 2
0.051
0.037
3.70
Block 3
0.055
0.034
2.67
*p < .05. **p < .01. ***p < .001

p
0.16
0.03*
0.05

∆R2
0.04
0.00

R2 Change Statistics
F Change
p
5.32
0.62

.02*
.43

Hypothesis 2
Hypothesis 2 posited that there would be a quadratic relation between parental FOH
(HFS-PYC score) and adherence (DSMP-SR Parent Form score), such that parents with high and
low levels of fear would have children with poorer adherence relative to parents with moderate
levels of fear. To test hypothesis 2, a hierarchical regression analysis was conducted with
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adherence as the dependent variable. Parental anxiety was entered in block one to control for
general parental anxiety. Parental FOH (linear) was entered in block two to examine the fit of a
linear model. Parental FOH (squared) was entered in block three to examine the fit of a quadratic
model. Regression statistics are presented in Tables 6 and 7.
The results of the first block hierarchical regression analysis revealed a statistically
significant model, F(1,140) = 5.547, p = .020. The R2 value of .038 associated with this
regression model suggests that parental anxiety accounts for 3.8% of the variance in adherence.
The adjusted R2 value is .031.
The results of the second block hierarchical regression analysis revealed a model that was
not statistically significant, F(2,139) = 2.781, p = .065. The R2 value of .038 associated with this
regression model suggests that parental anxiety and parental FOH (linear) account for 3.8% of
the variance in adherence. The adjusted R2 value is .025. The decrease of the adjusted R2 value
from the previous model suggests that the addition of parental FOH (linear) did not improve the
model. Additionally, the R2 change value of < .001 associated with this regression model
suggests that the addition of parental FOH (linear) accounts for < .1% of the variation in
adherence. The inclusion of parental FOH (linear) did not produce a statistically significant
increase in variance accounted for in adherence, p = .821.
The results of the third block hierarchical regression analysis revealed a statistically
significant model, F(3,138) = 2.916, p = .037. The R2 value of 0.060 associated with this
regression model suggests that parental anxiety, parental FOH (linear), and parental FOH
(quadratic) account for 6.0% of the variance in adherence. The adjusted R2 value is 0.039. The
increase of the adjusted R2 value from the previous model suggests that the addition of parental
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FOH (quadratic) improved the model by more than expected by chance. The R2 change value of
.021 associated with this regression model suggests that the addition of parental FOH (quadratic)
accounts for an additional 2.1% of the variation in adherence; however, this did not produce a
statistically significant increase in variance accounted for in adherence, p = .080. Of note, the
positive standardized regression coefficient of the quadratic term (β = 0.15) describes a parabola
that opens upward, the opposite direction of that hypothesized. Overall, the results of the
analyses did not support the second hypothesis that there would be a quadratic relation between
parental FOH and adherence.

Table 6: Linear Model of Predictors of Adherence
Regression Coefficients
B
SE B
β

Statistical Significance
t
p

Block 1
(Constant)
63.11
1.23
51.17
< .001***
Parental anxiety
-0.43
0.18
-0.20
-2.36
.020*
Block 2
(Constant)
63.18
1.27
49.59
< .001***
Parental anxiety
-0.44
0.19
-0.20
-2.30
.023*
Parental FOH (linear)
0.01
0.05
0.02
0.23
.821
Block 3
(Constant)
61.92
1.45
42.64
< .001***
Parental anxiety
-0.46
0.19
-0.21
-2.42
.017*
Parental FOH (linear)
-0.01
0.05
-0.01
-0.13
.893
Parental FOH (quadratic)
0.00
0.00
0.15
1.76
.080
Note. Parental FOH (linear) was mean-centered. Parental FOH (quadratic) is the linear term
squared.
*p < .05. **p < .01. ***p < .001
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Table 7: Model Summary of Hierarchical Regression Model with Adherence as Dependent
Variable
R2
Block 1
0.038
Block 2
0.038
Block 3
0.060
*p < .05. **p < .01. ***p < .001

Overall Model Fit
adj R2
F
p
0.031
5.55
0.02*
0.025
2.78
0.07
0.039
2.92
0.04*

∆R2
0.00
0.02

R2 Change Statistics
F Change
p
0.05
3.10

.82
.08

Hypothesis 3
Hypothesis 3 posited that adherence (DSMP-SR Parent Form score) would mediate the
relation between parental FOH (HFS-PYC score) and glycemic control (HbA1c). The proposed
mediation analysis to test hypothesis 3 was not conducted. One condition for mediation is that
the independent variable (parental FOH) predicts the mediator (adherence) (Baron & Kenny,
1986; Kim, 2016). As reported for hypothesis 2, controlling for parental anxiety, the linear term
of parental FOH did not predict adherence significantly. Although adding the quadratic term of
parental FOH improved the model, it did not produce a statistically significant increase in
variance accounted for in adherence. Further, the standardized regression coefficient of the
quadratic term (β = 0.15) was not significant, p = .080. Thus, we can conclude that this condition
was not met, for either the linear or quadratic terms for parental FOH, and that mediation
analysis was not appropriate.
Nevertheless, the relation between adherence and HbA1c was examined. Based on
previous research (Wysocki et al., 2012), it was expected that there would be a moderate
relationship between these variables; however, results of the Pearson’s correlation indicated that
there was no significant relationship between these variables, r(141) = -.093, p = .267.
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Exploratory Analyses
A scatterplot of HFS-PYC and HbA1c data points was examined (see Figure 2). It
appeared that a quadratic relationship may exist for parents with low FOH. A median split
(median = 76) was performed to produce two groups based on HFS-PYC scores, low parental
FOH (n = 70) and high parental FOH (n = 73). Descriptive statistics for study variables of these
groups are presented in Table 8.

Figure 2: Scatterplot of HFS-PYC and HbA1c.
Note. Vertical line indicates median for HFS-PYC
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Table 8: Descriptive Statistics of Low and High Parental FOH Groups
Variable
BSI 18 (anxiety)
HFS-PYC
HbA1c
DSMP-SR

Low Parental FOH Group
Range
Mean (SD)
0 - 15
3.64 (3.52)
40 - 75
62.46 (9.02)
5.2 - 10.7
7.54 (1.19)
37 - 78
62.14 (9.23)

High Parental FOH Group
Range
Mean (SD)
0 - 21
6.12 (5.33)
76 - 117
92.45 (12.50)
5.7 - 10.7
7.97 (1.06)
27 - 78
60.05 (11.19)

A hierarchical regression analysis, identical to that for hypothesis 1, was conducted on
the low parental FOH group. Regression statistics are presented in Tables 9 and 10.
The results of the first block hierarchical regression analysis revealed a model that was
not statistically significant, F(1,68) = 0.184, p = .670. The R2 value of .003 associated with this
regression model suggests that parental anxiety accounts for 0.3% of the variance in HbA1c. The
adjusted R2 value is -.012.
The results of the second block hierarchical regression analysis also revealed a model that
was not statistically significant, F(2,67) = 1.356, p = .265. The R2 value of .039 associated with
this regression model suggests that parental anxiety and parental FOH (linear) account for 3.9%
of the variance in HbA1c. The adjusted R2 value is .01. The increase of the adjusted R2 value
from the previous model suggests that the addition of parental FOH (linear) improved the model
by more than expected by chance. Additionally, the R2 change value of .036 associated with this
regression model suggests that the addition of parental FOH (linear) accounts for an additional
3.6% of the variation in HbA1c; however, the inclusion of parental FOH (linear) does not
produce a statistically significant increase in variance accounted for in HbA1c, p = .117.
The results of the third block hierarchical regression analysis revealed a model that was
statistically significant, F(3,66) = 2.961, p = .039. The R2 value of .119 associated with this
44

regression model suggests that parental anxiety, parental FOH (linear), and parental FOH
(quadratic) account for 11.9% of the variance in HbA1c. The adjusted R2 value is .079. The
increase of the adjusted R2 value from the previous model suggests that the addition of parental
FOH (quadratic) improved the model by more than expected by chance. The R2 change value of
.080 associated with this regression model suggests that the addition of parental FOH (quadratic)
accounts for an additional 8% of the variation in HbA1c. The inclusion of parental FOH
(quadratic) produces a statistically significant increase in variance accounted for in HbA1c, p =
.017. The positive standardized regression coefficient of the quadratic term (β = 1.038) describes
a parabola that opens upward, the direction of that hypothesized.

Table 9: Linear Model of Predictors of HbA1c, Low Parental FOH Group
Regression Coefficients
B
SE B
β

Statistical Significance
t
p

Block 1
(Constant)
7.48
0.21
36.22
< .001***
Parental anxiety
0.02
0.04
0.05
0.43
.670
Block 2
(Constant)
7.87
0.32
24.32
< .001***
Parental anxiety
0.01
0.04
0.04
0.33
.740
Parental FOH (linear)
0.03
0.02
0.19
1.59
.117
Block 3
(Constant)
8.66
0.45
19.25
< .001***
Parental anxiety
0.02
0.04
0.05
0.43
.668
Parental FOH (linear)
0.16
0.06
1.19
2.80
.007**
Parental FOH (quadratic)
< 0.01
< 0.01
1.04
2.44
.017*
Note. Parental FOH (linear) was mean-centered. Parental FOH (quadratic) is the linear term
squared.
*p < .05. **p < .01. ***p < .001
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Table 10: Model Summary of Hierarchical Regression Model with HbA1c as Dependent
Variable, Low Parental FOH Group
Overall Model Fit
2
R
adj R2
F
Block 1
0.003
-0.012
0.184
Block 2
0.039
0.010
1.356
Block 3
0.119
0.079
2.961
*p < .05. **p < .01. ***p < .001

p
.670
.265
.039*

∆R2
0.036
0.080

R2 Change Statistics
F Change
p
2.524
5.970

.117
.017*

In the interest of exploration, the same analysis was conducted on the high parental FOH
group, but no significant findings were identified.
The relation between parental FOH and glycemic control was further examined by
grouping HFS-PYC data based on distance from its mean. Five groups were created that
included data within 1 SD from the mean (moderate), data between 1 and 1.5 SDs from the mean
(moderately low and moderately high), and data greater than 1.5 SD from the mean (very low and
very high). Average HbA1c was calculated for each group (see Figure 3). There was a
statistically significant difference between groups as determined by one-way ANOVA (F(4, 138)
= 2.794, p = .029). A Tukey post hoc test revealed that HbA1c was statistically significantly
lower in the moderately low (7.09 ± 1.07 HbA1c) compared to the moderate (7.82 ± 1.10
HbA1c) group (p = .049).
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Figure 3: Mean HbA1c for Groups Based on Parent’s Level of Fear of Hypoglycemia.
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DISCUSSION
TID is a disease that requires intensive daily management. Unique developmental,
psychosocial, and physiological challenges further complicate T1D care in young children.
Given the increasing incidence of T1D, especially among young children, it is important to
elucidate factors that affect T1D management and outcomes. An existing conceptual model of
T1D in young children posits that parental coping influences T1D management which in turn
influences T1D outcomes (Pierce et al., 2017). One parental coping factor that has been
examined in the literature is fear of hypoglycemia (FOH). While this model suggests that
parental FOH may influence adherence to disease management and glycemic control, among
studies that have examined these relations, results have been inconsistent. This study examined
novel, quadratic relations among parental FOH, adherence, and glycemic control in young
children with T1D. The hypothesized relation between parental FOH and glycemic control, such
that parents with high and low levels of fear would have children with poorer glycemic control
relative to parents with moderate levels of fear, was not supported. Likewise, the hypothesis that
there would be a quadratic relation between parental FOH and adherence, such that parents with
high and low levels of fear would have poorer adherence relative to parents with moderate levels
of fear, was not supported. Finally, given these results, the hypothesis that adherence would
mediate the relation between parental FOH and glycemic control was also not supported.
Although the expected relation between the full range of parental FOH and glycemic
control was not supported, exploratory analyses revealed a potentially notable result. When only
the responses of parents who reported very low to moderate levels of FOH were examined, the
proposed quadratic relation emerged. Within this low parental FOH group, there was a quadratic
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relation between parental FOH and glycemic control. More specifically, within this group, those
with the highest and lowest levels of fear had children with higher HbA1c, relative to parents
with moderate levels of fear. This relation was not found among the responses of parents who
reported moderate to very high levels of FOH (i.e., the high parental FOH group); there was
neither a significant linear nor quadratic relation between parental FOH and glycemic control
within this group. Yet, of note, the mean HbA1c was higher in the high parental FOH group (M
= 7.97, SD = 1.06) than in the low parental FOH group (M = 7.54, SD = 1.19).
Given the quadratic relation identified in the low parental FOH group, along with the
overall higher HbA1c levels in the high parental FOH group, these finding suggest that both
very low and moderate to very high levels of FOH among parents of young children with T1D
may be a risk factor for poorer glycemic control, whereas a moderately low level of FOH may be
a protective factor for good glycemic control. Thus, whereas it was originally hypothesized that a
moderate level of FOH would be associated with optimal glycemic control in young children
with T1D, these findings suggest that a moderately low level of FOH may be associated with the
best glycemic control.
Although more complex than originally hypothesized, this relation between parental FOH
and glycemic control may provide a possible explanation for the inconsistencies that have been
reported in the literature. Most studies have tested a linear relationship (e.g., Clarke et al., 1998;
Freckleton et al., 2014; Gonder-Frederick et al., 2011; Gonder‐Frederick et al., 2006; Haugstvedt
et al., 2010; Hawkes et al., 2014; Johnson et al., 2013; Pate et al., 2016; Patton et al., 2007, 2008,
2017; Van Name et al., 2018; Viaene et al., 2017), and the findings of this study provide
preliminary support for a nonlinear relationship. Despite the abundant use of linear tests,
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researchers have suggested, theoretically, that both the low and high extremes of FOH may be
associated with poorer outcomes, with the optimal level lying somewhere in the middle (e.g.,
Cox et al., 1987; Driscoll et al., 2016; Gonder‐Frederick et al., 2006; Patton et al., 2007; Pierce et
al., 2017). The exploratory findings of this study provide preliminary empirical support for this
long-held theoretical postulation.
It was hypothesized that adherence would mediate the relation between parental FOH and
glycemic control, but the results of this study do not support this hypothesis. There are several
possible explanations for this unexpected result. It is possible that, despite acceptable reliability
(Cronbach’s alpha coefficient is .76), this hypothesis was not supported due to failure to
accurately measure adherence. T1D adherence includes multifaceted daily health behaviors,
which may be hard to capture accurately. There are advantages and disadvantages of every
method of measuring adherence, including structured interviews, self-report questionnaires, daily
diaries, clinician-completed questionnaires, direct patient observation, and electronic monitoring,
and there is no single gold standard of assessment for this important variable (Berg & Arnsten,
2006; Clifford et al., 2014; Gonzalez & Schneider, 2011; Quittner et al., 2008; Stirratt et al.,
2015; Wysocki et al., 2012). Advantages of self-report questionnaires, such as that utilized in this
study, include low cost, noninvasiveness, ease of administration, and low participant burden
(Berg & Arnsten, 2006; Stirratt et al., 2015). However, disadvantages include the potential for
inaccurate recall or memory bias, as well as vulnerability to social desirability bias (Berg &
Arnsten, 2006; Gonzalez & Schneider, 2011; Stirratt et al., 2015). Given the lack of a gold
standard measure of adherence, Quitner et al. (2008) have recommended triangulating two or
more methods of adherence assessment, for example, combining data from self-report measures
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and electronic monitoring, such as blood glucose monitors. Indeed, the one study that reported a
significant indirect effect of children’s FOH on HbA1c through adherence (Jurgen et al., 2020)
measured adherence by creating a composite adherence score based on data from self- and
parent-report and blood glucose meter printouts.
Additionally, the measure of adherence utilized in this study, the Diabetes SelfManagement Profile – Self Report (DSMP-SR) Parent Form, may not be appropriate for parents
of young children, as it has only been validated on a sample of parents of children and
adolescents ages 8–17 (Wysocki et al., 2012). Some items may not apply well to young children.
For example, item 1 states, “In the past 3 months, how often has your child gotten exercise such
as running, skateboarding, bike riding, swimming, skating, or playing any sports for at least 20
minutes?” This question may be confusing for parents of young and very young children who are
perhaps just learning to crawl and walk. Further, many of the items ask the parent what the child
does to manage his or her diabetes. For example, item 5 states, “If your child thinks a low blood
sugar is happening, how often does your child do a blood sugar check before treating?” Given
that it is unlikely that young and very young children are performing blood sugar checks
independently, it would be reasonable for the parent to select, “Never check before treating a low
blood sugar,” or, just as reasonably, mentally manipulate the question and respond according to
how often they themselves check. The DSMP-SR parent scores in the present study (M = 61.08,
SD = 10.29) were slightly higher than originally published DSMP-SR parent scores (M = 54.7,
SD = 12.6) (Wysocki et al., 2012), suggesting parents likely answered how they themselves have
taken care of their child’s diabetes, and possibly indicating the presence of social-desirability
response bias. This would also help explain the much lower correlation between adherence and
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HbA1c in the present study (r = -.09) than in the original validation study (r = -.46) (Wysocki et
al., 2012).
Alternately, it is possible that this hypothesis was not supported because adherence is
simply not a mediator of the relation between parental FOH and glycemic control. No identified
studies reported a significant relation between parental FOH and adherence; this has only been
described theoretically. Although Wysocki et al. (2012) reported a moderate effect size between
adherence and HbA1c (r = -.46), a large meta-analysis that examined this relation across 21
pediatric T1D studies reported a lower mean effect size (-0.28) (Hood et al., 2009). Of those 21
studies, only two had a sample of children with a mean age under 7, and one of those (Chisholm
et al., 2007) reported a relation that was actually in the opposite direction (r = .22). Thus, while
the relation between adherence and glycemic control has a strong theoretical rationale, the
relation has not been found to be particularly robust in the literature, especially for parents of
young children. Jurgen et al. (2020) found that adherence only marginally mediated the
relationship between FOH and glycemic control (p < .10), and once again, this finding was not in
the direction they had originally hypothesized.
Finally, it is possible that this hypothesis was not supported in this study because the
relations among parental FOH, adherence, and glycemic control are more complex than a simple
mediation. Retuning to Pierce et al.’s (2017) conceptual model, there are likely numerous parent
and child factors that impact management and outcomes of T1D in young children; and the
relations among these variables may not be straightforward. Exploratory analyses in the present
study suggested that both very low and moderate to high parental FOH may be associated with
poorer glycemic control than low (but not very low) parental FOH, supporting a nonlinear
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relationship. Although adherence was conceptualized as a single construct for this study, several
categories of adherence have been proposed, such as intentional nonadherence (purposefully
altering the treatment regimen) and unintentional nonadherence (forgetting to attend to the
treatment regimen) (Wroe, 2002). Wroe (2002) found that intentional nonadherence was more
strongly associated with the individual’s decisional balance of reasons for and against adherence,
such as burden. To improve overall understanding of adherence, she recommended separating
these constructs. Thus, other parent and child factors, nonlinear relationships, and latent
categories may all contribute to more complex relations among parental FOH, adherence, and
glycemic control than were examined in the present study.
Despite the lack of support for the proposed relations, this study has several strengths.
This study adds to the relatively scare literature on fear of hypoglycemia in the parents of young
children with T1D, which is important given the increasing incidence of TID among young
children. As recommended by Patton et al. (2008), this study statistically controlled for parents’
level of general anxiety to aid in understanding the construct of parental FOH broadly, and HFSPYC scores more specifically. It also offers preliminary support for a nonlinear relationship
between parental FOH and glycemic control, which may be useful for helping to explain some of
the inconsistent findings on the relations between these factors previously reported in the
literature. Findings also suggest that there may be an optimal level of parental FOH that is
associated with the best glycemic control.
This study also has limitations. Data was collected at one time-point. The cross-sectional
design does not allow for conclusions about causation. The sample was relatively homogeneous;
parents were mostly non-Hispanic, white, mothers with above average educational attainment,
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occupational categories, and household incomes, which is not representative of the population of
parents of young children with T1D. Mayer-Davis et al. (2017) reported that the annual rate of
increase in incidence of T1D is greater among children of minority racial and ethnic groups than
children who are non-Hispanic white. Given the racial-ethnic disparities that have been identified
in T1D management and outcomes (Willi et al., 2015), the homogenous sample in this study
limits generalization. For example, insulin pump use is associated with improved glycemic
control in children with T1D (Scrimgeour et al., 2007; Weissberg-Benchell et al., 2003), yet
more children who are white use insulin pumps than children who are black or Hispanic (Willi et
al., 2015). Additionally, children who are black have higher HbA1c and have experienced more
frequent DKA and severe hypoglycemic events, compared to children who are white or Hispanic
(Willi et al., 2015). Furthermore, most children in the sample were using CGMs, and the use of
CGMs is associated with better adherence (Diabetes Research in Children Network (DirecNet)
Study Group, 2006) and better glycemic control (Chase et al., 2001), and likely reduces parental
FOH (Burckhardt et al., 2018). If this study did measure adherence appropriately, the sample in
this study was highly adherent, which may also limit generalization.
Measurement issues, specifically in the assessment of adherence, were also a limitation in
this study. A self-report measure, developed for use with parents of older children, may not have
provided the most accurate information about adherence. While self-report measures are
notoriously susceptible to social desirability response bias, relatively few methods to assess
adherence to the complex management of this disease exist. Recommendations to include
multiple measures of adherence may overcome the limitations of a single, self-report measure.
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Future research should continue to explore whether there is an optimal level of parental
FOH that is associated with the best glycemic control, and if so, test the direction of this
relationship using longitudinal research designs. There are several active and recently completed
clinical trials that aim to reduce FOH (U.S. National Library of Medicine, n.d.-a) which may
provide insight into the causal relation between FOH and glycemic control, in addition to other
important outcomes. Future research may include measures of glycemic control beyond HbA1c.
Agiostratidou et al. (2017) recommended the use of clinically meaningful outcomes of T1D
besides HbA1c, including hypoglycemia, hyperglycemia, time in range, and DKA. Another
important outcome that should be investigated is quality of life, an essential outcome in health
care (Varni et al., 2003). Future studies should continue to explore the mechanisms of the
relation between parental FOH and glycemic control. Although this study failed to demonstrate
the role of adherence in this relation, it is nonetheless likely to play a key part. Measurement of
adherence may be improved by integrating data from several sources, including self-report and
electronic monitors, such as CGMs, to form composite adherence scores.
Broadly, future research should continue to examine the parent and child factors that
impact the management and outcomes of T1D in young children. As the incidence of T1D
continues to rise in this population, it will be especially important to increase understanding of
barriers and facilitators of achieving good glycemic control to prevent short-term and long-term
negative consequences in an effort to improve the health and quality of life among young
children with T1D and their parents.
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